$0.03
(Market cap
$1,346 Mln
Recently Viewed
Clear AllMarket cap
$1,346 Mln
Revenue (TTM)
$239 Mln
P/E Ratio
--
P/B Ratio
3.9
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
28.1
Debt to Equity
0.1
Book Value
$6.9
EPS
$-1.6
Face value
--
Shares outstanding
49,512,749
CFO
$147.57 Mln
EBITDA
$140.50 Mln
Net Profit
$84.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
STAAR Surgical (STAA)
| 18.3 | 35.2 | 55.8 | 43.6 | -25.0 | -25.9 | 13.6 |
|
BSE Sensex
| -9.0 | 5.0 | -8.1 | -4.3 | 7.6 | 9.8 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
STAAR Surgical (STAA)
| -4.9 | -22.0 | -35.7 | -46.8 | 15.2 | 125.2 | 10.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
STAAR Surgical (STAA)
|
27.3 | 1,346.3 | 239.4 | -80.5 | -19.2 | -21.7 | -- | 3.9 |
| 8.0 | 5,434.7 | 6,552.2 | -551.4 | -6.1 | -9.9 | -- | 1.0 | |
| 299.5 | 8,082.3 | 2,589.9 | 168.8 | 21.4 | 2.5 | 49.7 | 1.2 | |
| 38.0 | 5,600.3 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.3 | |
| 134.7 | 8,206.7 | 551.4 | -189.3 | -15.6 | -26.3 | -- | 12.2 | |
| 86.8 | 5,566.3 | 1,541.6 | 233.6 | 21.6 | 21.4 | 25.1 | 5.1 | |
| 178.2 | 9,345.7 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.5 | 13.0 | |
| 324.6 | 12,795.7 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72 | 9.0 | |
| 124.6 | 6,610.0 | 738.3 | 48.9 | 11.4 | 2.4 | 136.3 | 3.1 | |
| 31.5 | 13,298.7 | 6,178.4 | 626.5 | 13.0 | 11.9 | 21.8 | 2.5 |
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens... product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. Address: 25510 Commercentre Drive, Lake Forest, CA, United States, 92630 Read more
President, CEO & Chairman
Mr. Thomas G. Frinzi
President, CEO & Chairman
Mr. Thomas G. Frinzi
Headquarters
Lake Forest, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of STAAR Surgical Company (STAA) is $27.32 (NASDAQ) as of 05-May-2026 10:38 EDT. STAAR Surgical Company (STAA) has given a return of -24.95% in the last 3 years.
Since, TTM earnings of STAAR Surgical Company (STAA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-14.23
|
3.33
|
|
2024
|
-59.22
|
3.01
|
|
2024
|
--
|
--
|
|
2023
|
71.99
|
3.98
|
|
2023
|
--
|
--
|
The 52-week high and low of STAAR Surgical Company (STAA) are Rs 30.81 and Rs 15.59 as of 05-May-2026.
STAAR Surgical Company (STAA) has a market capitalisation of $ 1,346 Mln as on 04-May-2026. As per SEBI classification, it is a Small Cap company.
Before investing in STAAR Surgical Company (STAA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.